IRIS
CAVESTRO, Giulia Martina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.643
AS - Asia 4.352
EU - Europa 3.341
SA - Sud America 687
AF - Africa 272
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 14.308
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.467
SG - Singapore 1.943
CN - Cina 1.428
SE - Svezia 650
IE - Irlanda 619
UA - Ucraina 528
BR - Brasile 522
FI - Finlandia 433
DE - Germania 404
HK - Hong Kong 319
VN - Vietnam 252
TR - Turchia 210
ZA - Sudafrica 181
NL - Olanda 169
IT - Italia 151
GB - Regno Unito 125
CA - Canada 114
RU - Federazione Russa 94
AR - Argentina 71
CI - Costa d'Avorio 54
IN - India 40
MX - Messico 37
FR - Francia 35
BD - Bangladesh 29
BE - Belgio 24
IQ - Iraq 20
EC - Ecuador 19
LT - Lituania 19
PL - Polonia 19
CO - Colombia 17
ES - Italia 14
PE - Perù 14
IR - Iran 13
PY - Paraguay 13
UZ - Uzbekistan 13
JP - Giappone 11
RO - Romania 10
CL - Cile 9
PK - Pakistan 9
VE - Venezuela 9
AZ - Azerbaigian 8
CZ - Repubblica Ceca 8
ID - Indonesia 8
KE - Kenya 8
AT - Austria 7
EG - Egitto 7
EU - Europa 7
MA - Marocco 7
TN - Tunisia 7
BO - Bolivia 6
PA - Panama 6
UY - Uruguay 6
GT - Guatemala 5
IL - Israele 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
GE - Georgia 4
JO - Giordania 4
MD - Moldavia 4
RS - Serbia 4
AL - Albania 3
AU - Australia 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
HU - Ungheria 3
NO - Norvegia 3
PH - Filippine 3
SA - Arabia Saudita 3
AM - Armenia 2
DZ - Algeria 2
HN - Honduras 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
PS - Palestinian Territory 2
PT - Portogallo 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GI - Gibilterra 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
MU - Mauritius 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
Totale 14.295
Salva come PNG Salva come JPEG
Città #
Singapore 919
Chandler 859
Dublin 616
Ashburn 582
Jacksonville 538
Santa Clara 483
Dearborn 401
Hong Kong 315
Beijing 279
Boardman 255
Nanjing 252
Izmir 174
Johannesburg 173
Dallas 157
Princeton 154
San Mateo 147
Ann Arbor 122
Ho Chi Minh City 118
Shanghai 114
Munich 105
New York 92
Shenyang 84
Toronto 83
Wilmington 81
Los Angeles 77
Helsinki 68
Moscow 68
Nanchang 60
Abidjan 54
Hebei 53
São Paulo 51
Kunming 47
Tianjin 45
Changsha 42
Hanoi 41
Hefei 40
Jiaxing 39
Jinan 39
Buffalo 35
Turku 30
Norwalk 29
Kocaeli 26
Woodbridge 26
Parma 25
Brussels 23
Frankfurt am Main 22
Guangzhou 22
Houston 20
Hangzhou 19
Zhengzhou 19
Des Moines 18
Columbus 17
Denver 17
Pune 16
Stockholm 16
Taranto 16
Montreal 15
Warsaw 15
Council Bluffs 14
London 14
Seattle 14
Grafing 13
Rio de Janeiro 13
Boston 12
Chicago 12
Ningbo 12
Phoenix 12
San Jose 12
Belo Horizonte 11
Brasília 11
Bremen 11
Cambridge 11
Hải Dương 11
Lima 11
San Gregorio di Catania 11
Tashkent 11
Brooklyn 10
Orem 10
Porto Alegre 10
Auburn Hills 9
Curitiba 9
Poplar 9
San Francisco 9
Fortaleza 8
Messina 8
Quito 8
Atlanta 7
Baku 7
Bari 7
Da Nang 7
Leawood 7
Nairobi 7
Nuremberg 7
Rio Saliceto 7
Tokyo 7
Baghdad 6
Campina Grande 6
Chengdu 6
Düsseldorf 6
Fremont 6
Totale 8.652
Salva come PNG Salva come JPEG
Nome #
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 199
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 154
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 148
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 147
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 141
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 140
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 138
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 135
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 133
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 132
Association of keratin 8 gene mutation with chronic pancreatitis 130
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 130
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 130
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 129
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 129
Serum pepsinogen II for early assessment of success of H. pylori eradication 129
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 128
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 126
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 126
Bovine lactoferrin as a rescure treatment for Helicobacter pylori infection: results of a multicenter study 125
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 123
OC1.09.3 USEFULNESS OF GASTROPANEL FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASES 122
Associations of Spink-1 (N34S) and PRSS-1 (N29I and R122H) gene mutations and chronic pancreatitis in Italy 121
P.154 CONNECTIONS BETWEEN GENETICS AND CLINICAL DATA: ROLE OF MCP-1, CFTR, AND SPINK-1 IN THE SETTING OF ACUTE, ACUTE RECURRENT, AND CHRONIC PANCREATITIS 121
Gastro panel® for detection of atrophic gastritis: The “Parma model” 120
Rabepmzole in the treatment of non-responders GERD patients: a prospective six-month study 120
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 119
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 118
Esophagitis: acute therapy with omeprazole (Single Dosage Versus BID) 118
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 117
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 117
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 116
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 115
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 115
Gastroesophageal reflux disease in celiac patients: Preliminary results in 35 consecutive patients 114
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995) 112
A prospective therapeutical one-year study with pantoprazole for patients with oropharingeal picture of GERD 112
Lactoferrin in a 1-week triple therapy for eradication of H. pylori 111
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 111
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 111
A new marker for monitoring alcohol abuse? A pilot study on heavy drinkers 110
PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS 108
Usefulness of a serological panel test in the assessment of gastritis in symptomatic children 107
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 107
Chronic atrophic gastritis (GAC) and Helicobacter pylori infection eradication: a 3 years follow-up 105
LONG-TERM TREATMENT WITH MESALAMINE IN DIVERTICULAR DISEASE: A FIVE YEARS FOLLOW-UP STUDY 105
P.1.292: SYMPTOMATOLOGICAL PATTERN IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD), IRRITABLE BOWEL SYNDROME-DIARRHOEA (IBS-D), AND IBS-D PLUS SUDD 104
P.10 “GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY 104
Are there useful biomarkers for gastric cancer? 103
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis 103
A new curcumin-based one week therapy for eradication of H. pylori infection 103
Disappearance of gallbladder wall lesions after treatment with ursodeozycolic acid 102
Hypercalcemia due to ectopic secretion of parathyriod related protein from pancreatic carcinoma: a case report 100
“GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD 100
Study design biases in pancreatic inflammatory diseases. 99
Low alcohol and cigarette use is associated to the risk of developing chronic pancreatitis 99
Topography of gastric damage in H.pylori infection: evaluation by serum pepsinogens levels 98
DO PREBIOTICS RELIEVE CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-C) SYMPTOMS? A RANDOMIZED SINGLE BLINDED STUDY 97
Usefullness of gastropanel in different topography of H. pylori related chronic gastritis 95
CORRELATION BETWEEN LACTOSE H2-BREATH TEST AND CLINICAL DATA: IS IT POSSIBLE TO SELECT PATIENTS WHO NEED LACTOSE BREATH TEST? 95
Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. 95
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. 94
P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS 94
Recovery of gastric function after H. pylori eradication in subjects with body atrophic gastritis: a prospective four years study 94
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 93
Quality of life in patients with chronic pancreatitis 93
Lactoferrin: mechanism of action, clinical significance and therapeutic 93
Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer 93
Efficacy of mesalazine in the treatment of symptomatic diverticular disease 93
Serum pepsinogen II and gastrin-17 as markers of NSAIDs gastropathy 93
PANCREATIC PSEUDOCYSTS FOLLOWING ACUTE PANCREATITIS: RISK FACTORS INFLUENCING THERAPEUTIC OUTCOMES 92
Italian consensus guideline for chronic pancreatitis. 92
Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update 92
Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels 90
Gastroprotective effects of Amtolmetin Guacyl: a new non steroidal antiinflammatory drug that activates inducible gastric niytric oxide synthase 90
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 90
Assessment of H. pylori-related chronic gastritis by means of serum pepsinogens and oral sucrose 89
Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: prospective 4-year study 88
Nonteroidal drug-related gastroduodenal damage in the elderly 88
Lactoferrin in a one week triple therapy for eradication of H. Pylori 87
Therapy of NERD: single Vs double rabeprazole dosage 87
Serum pepsinogen II as a biomarker in management of H. pylori infection 87
Gastropanel as screening of gastric atrophy in primary care 86
Rabeprazole for the treatment of oropharingeal picture of GERD: a six-month prospective study 86
Diagnosis of H. pylori gastritis patterns by means of gastropanel 86
Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. 86
Serum pepsinogen II and Gastrin-17 (G-17) as markers of NSAIDS gastropathy 85
Clinical usefulness of serum pepsinogen II in the assessment of H. pylori infection 85
Clinical usefulness of Gastropanel (SPGI, SPGII, GASTRIN-17, HP SPECIFIC IgG) in the assessment of HP infection 84
HLA-DRB1*04 Allele contribute to the genetic susceptibility of chronic pancreatitis 84
TAP genes, coding for the transporters associated with antigen processing, contribute to the genetic predisposition to primary sclerosing cholangitis (PSC) 84
Relationship between direct and indirect methods for diagnosis of H.pylori infection 83
Macrohematuria caused by a fall in prothrombin activity as a clinical presentation of celiac disease. (I.F. 1.357) 83
Hyperbilirubinemia: does it matter? 83
Fisiopatologia pancreatica 82
Oral sucrose test and serum pepsinogens for evaluation of H. pylori chronic gastritis 82
‘Serological Biopsy’ in first degree relatives of patients with gastric cancer, affected by Helicobacter pylori 81
Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium 80
Lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: results of an open randomized trial 80
Rabeprazole in the treatment of non-responders GERD patients: a prospective six-month study 80
Totale 10.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.207
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.207
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 0 0 8 108 5 189 32 133 8
2021/2022777 14 15 10 36 43 17 80 108 32 87 92 243
2022/20232.618 294 253 169 234 238 325 7 188 797 9 81 23
2023/2024784 53 84 24 22 56 217 40 61 18 48 77 84
2024/20253.030 83 187 214 148 364 356 36 142 452 286 219 543
2025/20263.330 515 523 519 542 853 378 0 0 0 0 0 0
Totale 14.367